Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Pearce IP BioBlast™: w/e 31 July 2020

by | Aug 3, 2020

Significant biosimilar activities this week include

27 Jul 20 | EU | Celltrion announced the European Commission has granted marketing authorisation for Remsima® (biosimilar infliximab) subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

27 Jul 20 | The Centre for Biosimilars reported a study presented at the American Academy of Dermatology’s Virtual Meeting Experience 2020 which demonstrated  the safety, efficacy and immunogenicity of Boehringer Ingelheim’s Cyltezo® (biosimilar adalimumab) is comparable to AbbVie’s Humira®.

28 Jul 20 | Pfizer released its Q2 FY20  financial results.  Pfizer reported a 16% decrease in international revenues for Enbrel® (etanercept), attributing this decrease to biosimilar competition in Europe, Japan and Brazil.  Pfizer also revealed that it plans to launch Nyvepria® (biosimilar pegfilgrastim) in the US later this year.

28 Jul 20 | Amgen released its Q2 FY20 financial results.  Amgen reported the following impact to biologics/biosimilars global sales:

  • 6% year-over-year decrease for Prolia® (denosumab)
  • 9% year-over-year decrease for Enbrel® (etanercept)
  • 28% quarter-over-quarter decrease for Amgevita® (biosimilar adalimumab)
  • 28% year-over-year decrease for Neulasta (pegfilgrastim)
  • 35% year-over-year decrease for Neupogen® (filgrastim)
  • 28% year-over-year decrease for Epogen® (epoetin alfa)
  • 11% decrease year-over-year for Aranesp® (darbepoetin alfa)

These decreases were attributed to a range of factors including competition, COVID-19 impacts and lower net selling prices.

29 Jul 20 | EU | Shanghai Henlius Biotech and Accord Healthcare jointly announced the European Commission has approved Zercepac® (biosimilar trastuzumab) for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer.

30 Jul 20 | IN | Cadila Pharmaceuticals announced it has launched Ritucad® (biosimilar rituximab).  Ritucad® has been approved for Non-Hodgkin’s Lymphoma and rheumatoid arthritis.  This follows Cadila’s launch of Bevaro® (biosimilar bevacizumab) in India last week.

30 Jul 20 | US | Janssen announced the FDA approved an additional indication for Stelara® (ustekinumab) for paediatric patients with skin lesions or moderate to severe plaque psoriasis.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News